𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis

✍ Scribed by G. Kollerup; A. P. Hermann; K. Brixen; B. E. Lindblad; L. Mosekilde; O. H. Sørensen

Publisher
Springer
Year
1994
Tongue
English
Weight
392 KB
Volume
54
Category
Article
ISSN
1432-0827

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Estimation of the effect of salmon calci
Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers
✍ N. Munk Nielsen; P. Recke; M. A. Hansen; K. Overgaard; C. Christiansen 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 357 KB

We reviewed data on 42 postmenopausal women with established osteoporosis (forearm fracture or a low bone mass) who had been randomly treated for 1 year with either rectal salmon calcitonin (sCT), 100 IU daily (n = 25) or nasal sCT, 200 IU daily (n = 17) applying an estimation algorithm for bone los

Effect of intranasal salmon calcitonin t
Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: A dose-response study
✍ K. Overgaard 📂 Article 📅 1994 🏛 Springer 🌐 English ⚖ 578 KB

We examine the dose-related effect of intranasal salmon calcitonin (sCT) on the early postmenopausal bone loss and bone turnover; a 2-year, prospective, randomized, double-blind, placebo-controlled study was carried out with 134 healthy women who had passed a natural menopause within 6 months to 3 y

Effects of denosumab on bone turnover ma
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis
✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat